Pulmotect
PrivateLast Round
Series C
Sep 17, 2024
Total Funding Raised
$45.88M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pulmotect is a biotechnology company developing PUL-042, a clinical-stage, inhaled therapeutic that stimulates the innate immune system to provide broad-spectrum protection against respiratory infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pulmotect Comparables
Compare Pulmotect with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ENA Respiratory | 83% | |
| NorthLinks Bio | 78% | |
| Synairgen plc | 73% |
Pulmotect Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2024 | ||||
| Seed Round | Jan 16, 2024 | ||||
| Grant | May 30, 2023 | ||||
| Grant | Jan 27, 2021 | ||||
| Series B | Apr 4, 2018 | ||||
Series A | Apr 5, 2016 |
Pulmotect Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fannin Innovation Studio | Series A, Series C, Series B |
| Jefferson River Capital | Series B |
| U.S. Department of War | Grant |
| National Heart, Lung, and Blood Institute | Grant |
| Axil Capital | Series C |
| Aquinas Companies, LLC | Series B |
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 83% MoM, reaching 1.6K.
- Sep 17, 2024
$6M round led by Fannin Innovation Studio.
Pulmotect Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Pulmotect's valuation, stock price, and market status.
Is Pulmotect a public or private company?
Pulmotect is a private company.
What is the current stock price of Pulmotect?
Pulmotect is a private company with no public stock price. No recent secondary market data is available.
How much is Pulmotect worth (valuation)?
Valuation information for Pulmotect is not publicly available.
Can I buy Pulmotect stock?
Pulmotect shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Pulmotect's last funding round?
Pulmotect's most recent funding round was Series C on September 17, 2024.
Who are the main investors in Pulmotect?
Key investors in Pulmotect include Fannin Innovation Studio.
Will Pulmotect IPO soon?
No public IPO plans have been announced for Pulmotect.
How can I track Pulmotect secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pulmotect's secondary market activity and sign up for updates.